title: Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas.
abstract: We describe the construction of a recombinant bispecific antibody fragment in the diabody format with specificity for both the well-established human pancarcinoma associated target antigen EGP2 (epithelial glycoprotein 2, also known as the CO17-1A antigen or KSA) and the CD3epsilon chain of human TCR/CD3 complex. The murine anti-EGP2 (MOC31) single chain variable fragment (scFv) and the humanized anti-CD3 (Ucht1v9) scFv were cast into a diabody format (designated Dia5v9) using a short 5 amino acid Gly-Ser linker between immunoglobulin heavy-chain and light-chain variable domains. Purification of the poly-histidine tagged Dia5v9 was achieved from extracts of protease deficient Escherichia coli by IMAC chromatography. The Dia5v9 diabody showed strong binding to both EGP2 and CD3 in transfected cells. The in vitro efficacy of Dia5v9 in mediating tumor cell lysis by interleukin-2 activated human T cells appeared to be similar to that of the hybrid-hybridoma-derived BsF(ab')2 Bis1 (anti-EGP2/anti-CD3) in a standard 4-hr 51Cr-release assay. This small and partially humanized recombinant bispecific antibody fragment may be valuable for T-cell-based immunotherapeutical treatment protocols, retargeting activated peripheral blood T lymphocytes to lyse various human carcinomas in vivo.
authors.affiliation: GUIDE, University Hospital, Department of Clinical Immunology, Groningen, The Netherlands.
authors.forename: W
authors.initials: W
authors.lastname: Helfrich
authors.forename: B J
authors.initials: BJ
authors.lastname: Kroesen
authors.forename: R C
authors.initials: RC
authors.lastname: Roovers
authors.forename: L
authors.initials: L
authors.lastname: Westers
authors.forename: G
authors.initials: G
authors.lastname: Molema
authors.forename: H R
authors.initials: HR
authors.lastname: Hoogenboom
authors.forename: L
authors.initials: L
authors.lastname: de Leij
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000096:biosynthesis* / Q000378:metabolism / Q000494:pharmacology*; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology; D019556:COS Cells / Q000378:metabolism; D002850:Chromatography, Gel; D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D007116:Immunization, Passive; D007128:Immunoglobulin Fragments / Q000096:biosynthesis* / Q000378:metabolism / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000378:metabolism / Q000494:pharmacology; D012967:Sodium Dodecyl Sulfate; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D018033:Antibodies, Bispecific; D000951:Antigens, Neoplasm; D007128:Immunoglobulin Fragments; D011994:Recombinant Proteins; C050928:carcinoma-associated antigen 17-1A; D012967:Sodium Dodecyl Sulfate